BIOTRONIK Receives FDA Approval for Solia CSP S, World’s First Pacing Lead Specifically Designed For LBBAP 

Heart Rhythm 2026: Hands-On Demonstrations Available

BIOTRONIK Press Release

BIOTRONIK, a global leader in cardiovascular medical technology, today announced its Solia CSP S pacing lead has received approval from the U.S. Food and Drug Administration (FDA). With this approval, Solia CSP S is now commercially available in the United States, expanding access to a dedicated solution for Left Bundle Branch Area Pacing (LBBAP). 

Solia CSP S is the world’s first pacing lead to combine the support of a stylet-driven lead platform with the efficiency of a fixed helix – specifically engineered for LBBAP procedures. 

"FDA approval for the Solia CSP S pacing lead represents an important step forward in the continued advancement of physiologic pacing," said Larry Chinitz, MD, Director of Cardiac Electrophysiology at NYU Langone's Heart Rhythm Center, Co-Director of NYU Langone Heart and Principal Investigator of the BIO-CONDUCT study. "Investigator experiences from the BIO-CONDUCT IDE trial highlight the value of a product specifically engineered for LBBAP.” 

Indicated for LBBAP placement, the lead’s optimized helix, enhanced steerability, and simplified handling are designed to reduce preparation time while improving procedural efficiency and ease of delivery. 

"The Solia CSP S pacing lead provides a purpose-built solution long overdue for conduction system pacing," said Christopher Liu, MD, Medical Director of Cardiac Electrophysiology Services for the New York-Presbyterian – Weill Cornell Network. "With the combination of a stylet-driven platform and fixed helix, Solia CSP S is a new generation lead that can now be used to achieve physiologic pacing for our patients.” 

Physicians and healthcare professionals will have the opportunity to experience Solia CSP S firsthand at the Heart Rhythm Society Annual Scientific Sessions in Chicago, April 23–26, 2026. Attendees are invited to visit the BIOTRONIK booth for live demonstrations, hands-on training, and expert-led discussions on LBBAP and physiologic pacing. 

"With FDA approval, we reinforce our dedication to continued innovation in the critical field of CSP," said Ryan Walters, President, BIOTRONIK. "Solia CSP S reflects our commitment to advancing physiologic pacing and equipping clinicians with solutions that enhance patient outcomes."

For more information about Solia CSP S and BIOTRONIK’s LBBAP portfolio, please visit www.biotronik.com.